Clinical Trials Directory

Trials / Conditions / Nasopharyngeal Carcinoma (NPC)

Nasopharyngeal Carcinoma (NPC)

38 registered clinical trials studyying Nasopharyngeal Carcinoma (NPC)31 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingBecotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
NCT07303283
Kai HuPhase 2
Not Yet RecruitingIntegrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients
NCT07247201
Singapore General HospitalPhase 1 / Phase 2
RecruitingBecotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
NCT07459296
First Affiliated Hospital of Guangxi Medical UniversityPhase 3
RecruitingHypofractionated Radiotherapy for Nasopharyngeal Carcinoma
NCT06796270
The Second Affiliated Hospital of Hainan Medical UniversityN/A
Not Yet RecruitingScipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasop
NCT07388758
Sun Yat-sen UniversityPhase 2
RecruitingProton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
NCT07340515
Man HuPhase 3
Not Yet RecruitingA Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in th
NCT07252375
Fujian Cancer HospitalPhase 2
RecruitingReduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngea
NCT07328841
Ming-Yuan ChenPhase 3
RecruitingIparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatme
NCT07101744
Sun Yat-sen UniversityPhase 2
RecruitingInduction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasophary
NCT07277764
Jiangxi Provincial Cancer HospitalPhase 2
Not Yet RecruitingMolecular Research on Predictive Efficacy and New Therapeutic Targets for Nasopharyngeal Carcinoma
NCT07198802
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not Yet RecruitingPrecise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinomar
NCT07137052
The First Affiliated Hospital of Xiamen University
RecruitingSSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT in NPC
NCT06982300
University Medical Center GroningenPhase 1 / Phase 2
RecruitingIndividualized Neck Cervical Irradiation Prophylaxis Trial of NPC
NCT07303023
Fudan UniversityPhase 3
Not Yet RecruitingToripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcin
NCT07136519
Affiliated Hospital of Guangdong Medical UniversityPhase 2
RecruitingPhase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Meta
NCT07188584
Ming-Yuan ChenPhase 3
Not Yet RecruitingIvonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
NCT07064902
Sun Yat-sen UniversityPhase 2
Not Yet RecruitingTC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm C
NCT06987123
Sun Yat-sen UniversityPhase 2
Not Yet RecruitingPD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma
NCT06900218
Sun Yat-sen UniversityPhase 3
RecruitingA Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or In
NCT06839066
Shanghai Henlius BiotechPhase 2
RecruitingToripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT06712888
Sun Yat-sen UniversityPhase 3
Not Yet RecruitingKSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical
NCT06752473
Kousai Bio Co., Ltd.EARLY_Phase 1
RecruitingAn International Study on Pediatric Patients With Rare Tumors.
NCT07072143
Azienda Ospedaliera di Padova
RecruitingComparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyng
NCT06870435
Ming-Yuan ChenN/A
Enrolling By InvitationPrognostic Value of TIL in Nasopharyngeal Carcinoma
NCT06763640
Jiangxi Provincial Cancer Hospital
RecruitingEffect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
NCT07085988
Jiangxi Provincial Cancer HospitalPhase 2
RecruitingComparison of Multi-omics Models for Early Nasopharyngeal Carcinoma Screening: CfDNA Methylation, EBV DNA, and
NCT06763289
First Affiliated Hospital, Sun Yat-Sen University
Not Yet RecruitingTreatment with Intensity Modulated Radiotherapy on the Change of Cognitive Function in Nasopharyngeal Carcinom
NCT06695936
Sun Yat-sen University
Active Not Recruiting"Xijiang Project" Screening Cohort for NPC
NCT06787456
Ming-Yuan Chen
Not Yet RecruitingNeoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage Ta
NCT06680115
First Affiliated Hospital of Guangxi Medical UniversityPhase 2
RecruitingConcurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyn
NCT06611150
Sun Yat-sen UniversityPhase 1
Active Not RecruitingLong-term Outcomes of Early-stage Nasopharyngeal Carcinoma Patients Treated with Radiotherapy Alone
NCT06612697
Taichung Veterans General Hospital
CompletedCompassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma
NCT06676293
Chang Gung Memorial HospitalN/A
Active Not RecruitingBrain Alterations Based on Multiplex MR Imaging in Nasopharyngeal Carcinoma Patients After Treatment, and Thei
NCT07011329
Hubei Cancer Hospital
RecruitingSapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma
NCT07327216
Affiliated Hospital of Guangdong Medical UniversityPhase 3
CompletedSafety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advance
NCT04215978
BeiGenePhase 1
Active Not RecruitingValidation of the 9th AJCC Staging System for NPC in Non-High-Incidence Areas in China
NCT07088861
Lirong Wu
No Longer AvailableExpanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignan
NCT02822495
Atara Biotherapeutics